Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS
Document Type and Number:
WIPO Patent Application WO/2021/155764
Kind Code:
A1
Abstract:
The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.

Inventors:
WANG ZAIQI (CN)
ZHANG JIANGWEI (CN)
Application Number:
PCT/CN2021/074371
Publication Date:
August 12, 2021
Filing Date:
January 29, 2021
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
INXMED NANJING CO LTD (CN)
International Classes:
A61P35/00; A61K31/506; C07D239/47
Domestic Patent References:
WO2010058032A22010-05-27
WO2010058032A22010-05-27
Foreign References:
CN108289892A2018-07-17
CN202010080757A2020-02-05
Other References:
ANONYMOUS: "Congratulations!INSTEC FAK inhibitors are clini cally approved in China", MEDICINE GUANLAN, 19 December 2019 (2019-12-19), XP055833930, Retrieved from the Internet
DOI TOSHIHIKO; YANG JAMES CHIH-HSIN; SHITARA KOHEI; NAITO YOICHI; CHENG ANN-LII; SARASHINA AKIKO; PRONK LINDA C.; TAKEUCHI YOSHITO: "Phase I Study of the Focal Adhesion Kinase Inhibitor BIĀ 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors", TARGETED ONCOLOGY, SPRINGER PARIS, PARIS, vol. 14, no. 1, 6 February 2019 (2019-02-06), Paris, pages 57 - 65, XP036720766, ISSN: 1776-2596, DOI: 10.1007/s11523-019-00620-0
Attorney, Agent or Firm:
LIU, SHEN & ASSOCIATES (CN)
Download PDF: